NSIM
PCVX icon

North Star Investment Management’s Vaxcyte PCVX Stock Holding History

North Star Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581 Hold
10
– – ﹤0.01% 1636
2026
Q1 		$581 Hold
10
– – ﹤0.01% 1571
2025
Q4 		$461 Buy
+10
New +$447 ﹤0.01% 1519

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

North Star Investment Management's PCVX Position: Q2 2026 in Review

North Star Investment Management held its Vaxcyte (PCVX) position steady in Q2 2026 at 10 shares worth $581. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

North Star Investment Management first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • North Star Investment Management held 10 shares of Vaxcyte worth $581 as of Q2 2026.
  • North Star Investment Management left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up ﹤0.01% of North Star Investment Management's portfolio in Q2 2026, its #1636 holding.
  • North Star Investment Management first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on North Star Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.